Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 1–25 of 37 studies in Caregiving published 2026 (page 1 of 2) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 37 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Caregiving” covers

Caregiving — Research on the people doing the caring: their health, their workload, and what support actually helps.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

This pilot randomized clinical trial demonstrated the feasibility, acceptability, and preliminary efficacy of LMH-4-DCP in reducing caregiver grief, with improvements in caregiver-care recipient relationship quality. 5 key findings →

Design: RCT Participants: 68 Evidence: preliminary

The effects on depression and other outcomes were consistent with those observed for in-person programs, suggesting the viability of well-designed automated intervention. 2 key findings →

Design: RCT Participants: 274 Evidence: moderate

Longer follow-up and testing across diverse LEP communities are needed to assess diagnosis, treatment initiation, and caregiver trajectories. 1 key finding →

Design: RCT Participants: 287 Evidence: moderate

One hundred sixteen participants consented and 93 (46 waitlist control, 47 intervention) were included in the analyses. 3 key findings →

Design: RCT Participants: 93 Evidence: null result

Peer support interventions suggest beneficial short-term effects on specific caregiver outcomes but lack long-term sustainability. 3 key findings →

Design: meta-analysis Participants: 1,680 Evidence: moderate

Future studies should prioritize short-term interventions and develop integrated approaches combining individual and group formats. 2 key findings →

Design: meta-analysis Participants: 750 Evidence: moderate

Our study included 467 caregivers. Most (92.5%) caregivers performed at least one health care interaction task. 5 key findings →

Design: cross-sectional Participants: 467 Evidence: low

At baseline, nearly one-third of caregivers reported moderate-to-severe burden (mean ZBI 31.4 ± 15.4), a prevalence that persisted at 6 months. 5 key findings →

Design: cohort study Evidence: moderate

A significant association between increased caregiver burden and BPSD in patients with AD was demonstrated, which may be associated with decreased caregiver healthcare and social care-related QOL. 2 key findings →

Design: cross-sectional Evidence: low

The caregivers in intervention group showed significant reductions in distress scores for dressing, personal hygiene, communication, and behavioural and psychological care problems at both the 6th and 12th week assessments. 5 key findings →

Participants: 125 Evidence: low

With the increased use of technological supports in residential care homes, there is growing interest in the use of real-time location systems (RTLS) to enhance safety and streamline care. 1 key finding →

Evidence: low

Family caregivers (n = 705) had a mean ± standard deviation (SD) age of 54.6 ± 11.5 years, 56.9% were male, and 84.0% cared for a parent or in-law with AD. 5 key findings →

Participants: 705 Evidence: low

These findings identify affiliate stigma as an important risk factor for dementia caregivers’ depressive symptoms, operating through both objective and emotional forms of social disconnection. 2 key findings →

Evidence: low

Family caregivers of individuals with Alzheimer’s Disease and Related Dementia (AD/ADRD) face significant emotional and logistical challenges that place them at heightened risk for stress, anxiety, and depression. 2 key findings →

Evidence: low

Progressive functional decline and behavioral disturbances in people with dementia place sustained emotional and practical demands on family caregivers, often resulting in chronic stress, anxiety, depression, and a high perceived caregiving burden. 2 key findings →

Evidence: low

BackgroundAlzheimers Disease and Related Dementias (ADRD) is a growing global public health challenge, and caregivers experience high rates of burden, unmet needs, and system failures. 1 key finding →

Evidence: low

Prior work suggests that perceived value may shape online support use, yet practical and trust-related barriers may still impede uptake even when beliefs are favorable. 5 key findings →

Design: cross-sectional Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed